Quantcast

Industry news that matters to you.  Learn more

Archives for July 2011

Proteome Sciences, Moffitt Cancer Center Collaborate on Clinical Mass Spectrometry Assays for Assessment of Cancer Patients

Proteome Sciences plc (“Proteome”) a global leader in applied proteomics has entered into a collaboration agreement with Moffitt Cancer Center (“Moffitt”). Under the agreement, Proteome will support research to develop mass spectrometry assays measuring certain key signalling and repair pathway proteins that can be adapted for tumour biopsy analysis in the clinic.

Metanomics Health Launches its Energy Metabolite Platform

Metanomics Health GmbH today announced the official launch of its new Energy Metabolite Platform. This targeted platform maps key metabolites affecting the energy status of a biological system. Metanomics Health GmbH, a Berlin based BASF Group company, is market leader in offering non-targeted and targeted metabolite profiling to healthcare customers.

Metabolon’s Vitamin D Deficiency Test Now Available for Patient Analysis

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced today that it is now offering a tandem mass spectrometry (LC/MS/MS) test for detection of Vitamin D deficiency. The test is being run in Metabolon’s high-complexity CLIA registered laboratory in Research Triangle Park, NC. This test is available for patient testing.

Personalized Medicine on the Horizon for BC Cancer Patients

Genome British Columbia and the BC Cancer Foundation have joined forces to announce a major step forward in applying the power of genomics to personalized medicine. The innovative partnership stems from the strong focus of both organizations on the potential of genomics to improve patient outcomes in BC.

TCGA Study Brings Ovarian Cancer Patients Closer to Personalized Medicine

In the June 30 issue of Nature, researchers from The Cancer Genome Atlas (TCGA) Research Network provide a large-scale integrative report on genetic mutations and pathways that distinguish the most common and aggressive type of ovarian cancer from other types of ovarian cancer as well as from other solid tumors. The disease is not defined by one or few cancer-driving genes but rather numerous mutations that individually occur in only a small number of cases. Given the degree of genomic disarray, the study results suggest that genomic structural variation is the driver of ovarian cancer. The findings may be helpful in guiding physicians to choose experimental treatments that are most likely to target molecular alterations effectively in patients with high-grade serous ovarian adenocarcinoma.